Scott Adams Ely, M.D.

Scott Ely

Dr. Ely's practice in hematopathologymainly involves the diagnosis of and prognostication for multiple myeloma (MM), lymphoma and leukemias. His research has beenin the areas of B cell lymphomas and plasma cell neoplasms (MM and monoclonal gammopathy of undetermined significance [MGUS]).Dr. Ely is co-director of the immunopathology core for the Specialized Center of Research for Multiple Myeloma. As such, hismain research focus is developing assays for cell cycle analysis at the single cell level, through the use of manual and automatedquantitative image analysis of immunohistochemistry. His work applies mainly on the use of such assays for drug developmentand efficacy monitoring in multiple myleoma and lymphoma patients. Through the utilization of these assays, his work has helpedin our understanding of the role of the cell cycle in these and other cancers, and it has led directly to the developmentof targeted therapies. Although development of these assays is ongoing, currently they are being used in 4 multi-center phase1/2 clinical trials.

Dr. Ely studied microbiology and English literature at Louisiana State University and Queen Mary College of the University of London.  He went to medical school at Tulane University School of Medicine and concurrently completed a masters degree in public health at the Tulane University School of Public Health and Tropical Medicine.  After graduation, he completed a general surgery internship at S.U.N.Y., Brooklyn, followed by an anatomic pathology and clinical pathology residency at Lenox Hill Hospital, in New York City.  After residency, he completed a hematopathology fellowship, followed by a post-fellowship year of basic science research at Cornell University Medical College.  He was appointed to the attending staff in the Hematopathology Division of the Department of Pathology in 1998.  Dr. Ely is board certified in anatomic pathology, clinical pathology, and hematology.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA: IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Mod Pathol doi: 10.1038/modpathol.2013.159. [Epub ahead of print], 2013.

Nardiello, Tricia, Jungbluth, Achim A., Mei, Anna, DiLiberto, Maurizio, Huang, Xiangao, Dabrowski, Ania, Andrade, Valeria C.C., Wasserstrum, Rebecca, Ely, Scott, Niesvizky, Ruben, Pearse, Roger, Coleman, Morton, Jayabalan, David S., Bhardwaj, Nina, Old, Lloyd J., Chen-Kiang, Selina, Cho, Hearn Jay. MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. Clinical cancer research. 2011;17:4309-4319.

Subramaniyam S, Fraser CR, Rao PH, Feldman E, Ely S, Mathew S. De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13. Leukemia & lymphoma. 2011;52:2195-2199.

John P. Leonard, Ann S. LaCasce, Mitchell R. Smith, Ariela Noy, Lucian R. Chirieac, Scott J. Rodig, Jian Q. Yu, Shankar Vallabhajosula, Steven M. Larson, Heiko Schoder, Patricia English, Donna S. Neuberg, Peter Martin, Michael M. Millenson, Scott A. Ely, Rachel Courtney, Naveed Shaik, Keith D. Wilner, Sophia Randolph, Annick D. Van den Abbeele, Selina Y. Chen-Kiang, Jeffrey T. Yap and Geoffrey I. Shapiro. Selective CDK4/6 Inhibition and Tumor Responses are Induced by PD0332991 In Patients with Mantle Cell Lymphoma.  Accepted for publication in Blood, January, 2012


Honors and Awards

Ciba-Geigy Award, “…given to the medical student who best exemplifies the ideals of community service,” Ciba-Geigy/Tulane University School of Medicine, New Orleans, LA 1989

AMA/Burroughs-Welcome Award, “... for outstanding qualities of leadership and service,” American Medical Association, Chicago, IL 1993

Concepts in Molecular Biology Scholarship, College of American Pathologists,

   American Society for Investigative Pathology, Bethesda, MD, 9/28/94

CAP Foundation Scholarship, Symposium on Automated Information Management in Clinical Laboratories, College of American Pathologists, Ann Arbor, MI 6/96